We are testing a new beta website for gov.scot go to new site

Menu

Contact Details

Scottish Government GM Policy Team
Saughton House
Broomhouse Drive
Edinburgh
EH11 3XD
 
0300 244 9503
 
Scottish Government GM Inspectorate
SASA
Roddinglaw Road
Edinburgh
EH12 9FJ
 
0131 244 8853

Research Release Applications

Enquiries relating to Part B applications should be addressed to the Scottish Government GM Inspectorate.

 

January 2013

Application for a Part B consent from Celladon Corporation to undertake a clinical trial of intracoronary drug MYDICAR (AAV1/SERCA2a) in subjects with heart failure.

Notice of the application to Scottish Ministers has been published in the Glasgow Herald.

Details of the application have been placed on the UK statutory public register which can be viewed by contacting the Defra Information Resource Centre, Ergo House, Horseferry Road, London, SW1P 2AL.

(email: defra.library@defra.gsi.gov.ik) or online at:

http://www.defra.gov.uk/environment/quality/gm/applications-consents/

The MYDICAR application (Part A1, Part A2, Part B) can obtained from the Scottish public register at Saughton House, Broomhouse Drive, Edinburgh, EH11 3XD

Consent letter issued to Celladon Corporation

 

September 2012

Application for a Part B Consent from BN ImmunoTherapeutics Inc to undertake a clinical trial of a vaccine PROSTVAC V/F in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer.

Notice of the application has been published in the Glasgow Herald.

BNIT Public Notice

Details of the application have been placed on the UK statutory public register which can be viewed by contacting the Defra Information Resource Centre, Ergon House, Horseferry Road, London SW1P 2AL (e-mail defra.library@defra.gsi.gov.uk) or online at:

http://www.defra.gov.uk/environment/quality/gm/applications-consents/

Alternatively you can view copies of the application on the Scottish public register at Saughton House, Broomhouse Drive, Edinburgh, EH11 3XD

Consent letter issued to BN ImmunoTherapeutics Inc.

December 2013

Consent Variation: Consent letter issued to Bavarian Nordic Inc (Formerly BN Immuno Therapeutics Inc)

December 2014

Consent Variation: Further extension to consent letter issued to Bavarian Nordic Inc (Formerly BN Immuno Therapeutics Inc)

January 2016

Letter of Termination: Bavarian Nordic trial in Scotland.

 

January 2009

Application for a Part B Consent from MedImmune LLC to evaluate MEDI-534 as a vaccine against Respiratory Syncytial Virus and Parainfluenza Virus Type 3 in small children.

This trial did not proceed. Consent closed 22 September 2011